172 related articles for article (PubMed ID: 33616655)
1. Alfacalcidol vs Calcitriol in the Management of Patient With Hypoparathyroidism: A Randomized Controlled Trial.
Saha S; Sreenivas V; Goswami R
J Clin Endocrinol Metab; 2021 Jun; 106(7):2092-2102. PubMed ID: 33616655
[TBL] [Abstract][Full Text] [Related]
2. Auditing the Efficacy and Safety of Alfacalcidol and Calcium Therapy in Idiopathic Hypoparathyroidism.
Saha S; Goswami R
J Clin Endocrinol Metab; 2019 Apr; 104(4):1325-1335. PubMed ID: 30608544
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics and pharmacodynamics of subcutaneous recombinant parathyroid hormone (1-84) in patients with hypoparathyroidism: an open-label, single-dose, phase I study.
Clarke BL; Kay Berg J; Fox J; Cyran JA; Lagast H
Clin Ther; 2014 May; 36(5):722-36. PubMed ID: 24802860
[TBL] [Abstract][Full Text] [Related]
4. Association of vitamin D and FGF23 with serum ferritin in hypoparathyroid thalassemia: a case control study.
Saki F; Salehifar A; Kassaee SR; Omrani GR
BMC Nephrol; 2020 Nov; 21(1):482. PubMed ID: 33198660
[TBL] [Abstract][Full Text] [Related]
5. Fibroblast growth factor-23 (FGF23) in patients with transient hypoparathyroidism: its important role in serum phosphate regulation.
Yamashita H; Yamazaki Y; Hasegawa H; Yamashita T; Fukumoto S; Shigematsu T; Kazama JJ; Fukagawa M; Noguchi S
Endocr J; 2007 Jun; 54(3):465-70. PubMed ID: 17464094
[TBL] [Abstract][Full Text] [Related]
6. Oral calcitriol versus oral alfacalcidol for the treatment of secondary hyperparathyroidism in patients receiving hemodialysis: a randomized, crossover trial.
Moe S; Wazny LD; Martin JE
Can J Clin Pharmacol; 2008; 15(1):e36-43. PubMed ID: 18192704
[TBL] [Abstract][Full Text] [Related]
7. Serum 1,25-Dihydroxyvitamin D as a Biomarker of the Absence of Hypercalciuria in Postsurgical Hypoparathyroidism.
García-Pascual L; Barahona MJ; Perea V; Simó R
J Clin Endocrinol Metab; 2017 Jan; 102(1):259-266. PubMed ID: 27813709
[TBL] [Abstract][Full Text] [Related]
8. Role of fibroblast growth factor 23 (FGF23) in the metabolism of phosphorus and calcium immediately after kidney transplantation.
Sánchez Fructuoso AI; Maestro ML; Calvo N; De La Orden V; Pérez Flores I; Vidaurreta M; Valero R; Fernández-Pérez C; Barrientos A
Transplant Proc; 2012 Nov; 44(9):2551-4. PubMed ID: 23146451
[TBL] [Abstract][Full Text] [Related]
9. Long-term treatment of 12 children with chronic hypoparathyroidism: a randomized trial comparing synthetic human parathyroid hormone 1-34 versus calcitriol and calcium.
Winer KK; Sinaii N; Reynolds J; Peterson D; Dowdy K; Cutler GB
J Clin Endocrinol Metab; 2010 Jun; 95(6):2680-8. PubMed ID: 20392870
[TBL] [Abstract][Full Text] [Related]
10. Randomized trial comparing pulse calcitriol and alfacalcidol for the treatment of secondary hyperparathyroidism in haemodialysis patients.
Kiattisunthorn K; Wutyam K; Indranoi A; Vasuvattakul S
Nephrology (Carlton); 2011 Mar; 16(3):277-84. PubMed ID: 21342321
[TBL] [Abstract][Full Text] [Related]
11. Effects of parathyroid hormone rhPTH(1-84) on phosphate homeostasis and vitamin D metabolism in hypoparathyroidism: REPLACE phase 3 study.
Clarke BL; Vokes TJ; Bilezikian JP; Shoback DM; Lagast H; Mannstadt M
Endocrine; 2017 Jan; 55(1):273-282. PubMed ID: 27734257
[TBL] [Abstract][Full Text] [Related]
12. Calcitriol dosage in osteomalacia, hypoparathyroidism and attempted treatment of myositis ossificans progressiva.
Stamp TC
Curr Med Res Opin; 1981; 7(5):316-36. PubMed ID: 6894416
[TBL] [Abstract][Full Text] [Related]
13. Parathyroid Hormone Replacement Therapy in Hypoparathyroidism: A Meta-Analysis.
Liu XX; Zhu XY; Mei GH
Horm Metab Res; 2016 Jun; 48(6):377-83. PubMed ID: 27254756
[TBL] [Abstract][Full Text] [Related]
14. Synthetic human parathyroid hormone 1-34 vs calcitriol and calcium in the treatment of hypoparathyroidism.
Winer KK; Yanovski JA; Cutler GB
JAMA; 1996 Aug; 276(8):631-6. PubMed ID: 8773636
[TBL] [Abstract][Full Text] [Related]
15. Hypoparathyroidism during pregnancy: treatment with calcitriol.
Salle BL; Berthezene F; Glorieux FH; Delvin EE; Berland M; David L; Varenne JP; Putet G
J Clin Endocrinol Metab; 1981 Apr; 52(4):810-3. PubMed ID: 6894151
[TBL] [Abstract][Full Text] [Related]
16. The effect of an oral sodium phosphate load on parathyroid hormone and fibroblast growth factor 23 secretion in normo- and hypercalciuric stone-forming patients.
Irzyniec T; Boryń M; Kasztalska J; Nowak-Kapusta Z; Maciejewska-Paszek I; Grochowska-Niedworok E
Clin Nutr; 2020 Dec; 39(12):3804-3812. PubMed ID: 32386861
[TBL] [Abstract][Full Text] [Related]
17. Effects on calcium homeostasis of changing PTH replacement therapy of postoperative hypoparathyroidism from intact PTH to teriparatide: a case series.
Bislev LS; Sikjaer T; Rejnmark L
Calcif Tissue Int; 2014 Oct; 95(4):374-81. PubMed ID: 25086672
[TBL] [Abstract][Full Text] [Related]
18. Changes in fibroblast growth factor 23 during treatment of secondary hyperparathyroidism with alfacalcidol or paricalcitol.
Hansen D; Rasmussen K; Pedersen SM; Rasmussen LM; Brandi L
Nephrol Dial Transplant; 2012 Jun; 27(6):2263-9. PubMed ID: 22140123
[TBL] [Abstract][Full Text] [Related]
19. Orthophosphate therapy decreases urinary calcium excretion and serum 1,25-dihydroxyvitamin D concentrations in idiopathic hypercalciuria.
Van Den Berg CJ; Kumar R; Wilson DM; Heath H; Smith LH
J Clin Endocrinol Metab; 1980 Nov; 51(5):998-1001. PubMed ID: 6893460
[TBL] [Abstract][Full Text] [Related]
20. Safety and Efficacy of Oral Human Parathyroid Hormone (1-34) in Hypoparathyroidism: An Open-Label Study.
Ish-Shalom S; Caraco Y; Khazen NS; Gershinsky M; Szalat A; Schwartz P; Arbit E; Galitzer H; Tang JC; Burshtein G; Rothner A; Raskin A; Blum M; Fraser WD
J Bone Miner Res; 2021 Jun; 36(6):1060-1068. PubMed ID: 33666947
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
